Yiling Yu

754 total citations
8 papers, 152 citations indexed

About

Yiling Yu is a scholar working on Genetics, Pathology and Forensic Medicine and Hematology. According to data from OpenAlex, Yiling Yu has authored 8 papers receiving a total of 152 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Genetics, 6 papers in Pathology and Forensic Medicine and 5 papers in Hematology. Recurrent topics in Yiling Yu's work include Chronic Lymphocytic Leukemia Research (7 papers), Lymphoma Diagnosis and Treatment (6 papers) and Chronic Myeloid Leukemia Treatments (5 papers). Yiling Yu is often cited by papers focused on Chronic Lymphocytic Leukemia Research (7 papers), Lymphoma Diagnosis and Treatment (6 papers) and Chronic Myeloid Leukemia Treatments (5 papers). Yiling Yu collaborates with scholars based in China, Australia and Singapore. Yiling Yu's co-authors include Jane Huang, David Simpson, Gavin Cull, Eric Holmgren, Andrew W. Roberts, Stephen Opat, James Hilger, William Novotny, Javier Muñoz and John F. Seymour and has published in prestigious journals such as Blood, Clinical Cancer Research and British Journal of Haematology.

In The Last Decade

Yiling Yu

8 papers receiving 152 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Yiling Yu China	6	122	117	47	44	39	8	152
Andrew Keezer United States	6	137 1.1×	117 1.0×	47 1.0×	77 1.8×	22 0.6×	14	160
Patricia Severns United States	6	236 1.9×	207 1.8×	84 1.8×	79 1.8×	25 0.6×	13	242
Elina Vervessou Greece	3	234 1.9×	195 1.7×	75 1.6×	74 1.7×	30 0.8×	4	244
Anouk de Jong United States	5	99 0.8×	66 0.6×	39 0.8×	26 0.6×	17 0.4×	7	116
Maité Cabes United Kingdom	5	100 0.8×	96 0.8×	18 0.4×	39 0.9×	47 1.2×	10	139
Sean D. Reiff United States	7	135 1.1×	102 0.9×	58 1.2×	32 0.7×	33 0.8×	13	163
Amy Sam United States	6	232 1.9×	193 1.6×	116 2.5×	79 1.8×	31 0.8×	14	276
Tommi Salmi United States	5	86 0.7×	75 0.6×	24 0.5×	23 0.5×	17 0.4×	11	96
Éric Durot France	6	65 0.5×	74 0.6×	16 0.3×	22 0.5×	21 0.5×	26	92
Elżbieta Iskierka‐Jazdzewska Poland	7	71 0.6×	84 0.7×	21 0.4×	26 0.6×	36 0.9×	25	110

Countries citing papers authored by Yiling Yu

Since Specialization

Citations

This map shows the geographic impact of Yiling Yu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yiling Yu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yiling Yu more than expected).

Fields of papers citing papers by Yiling Yu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yiling Yu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yiling Yu. The network helps show where Yiling Yu may publish in the future.

Co-authorship network of co-authors of Yiling Yu

This figure shows the co-authorship network connecting the top 25 collaborators of Yiling Yu. A scholar is included among the top collaborators of Yiling Yu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yiling Yu. Yiling Yu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

8 of 8 papers shown

1.

Liu, Yang, et al.. (2024). Zanubrutinib is effective in non-germinal-center B-cell-like diffuse large B-cell lymphoma with mutated CD79B , high TCL1A expression, or over- expressed MYC/BCL-2. Leukemia & lymphoma. 65(8). 1079–1089. 2 indexed citations

2.

Wang, Haitao, Wenjing Zhang, Yiwen Wang, et al.. (2023). P1219: BGB-16673, A BTK DEGRADER, OVERCOMES ON-TARGET RESISTANCE FROM BTK INHIBITORS AND PRESENTS SUSTAINABLE LONG-TERM TUMOR REGRESSION IN LYMPHOMA XENOGRAFT MODELS. HemaSphere. 7(S3). e24358c2–e24358c2. 7 indexed citations

3.

Xu, Pengpeng, Rong Shen, Shu Cheng, et al.. (2022). The Prognostic Significance of CD79B Mutation in Diffuse Large B-Cell Lymphoma: A Meta-analysis and Systematic Literature Review. Clinical Lymphoma Myeloma & Leukemia. 22(12). e1051–e1058.e1. 6 indexed citations

4.

Song, Yuqin, Mingyuan Sun, Junyuan Qi, et al.. (2022). A two‐part, single‐arm, multicentre, phase I study of zanubrutinib, a selective Bruton tyrosine kinase inhibitor, in Chinese patients with relapsed/refractory B‐cell malignancies. British Journal of Haematology. 198(1). 62–72. 20 indexed citations

5.

An, Gang, Daobin Zhou, Shu Cheng, et al.. (2021). A Phase II Trial of the Bruton Tyrosine-Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Relapsed/Refractory Waldenström Macroglobulinemia. Clinical Cancer Research. 27(20). 5492–5501. 25 indexed citations

6.

Trotman, Judith, Stephen Opat, David Gottlieb, et al.. (2020). Zanubrutinib for the treatment of patients with Waldenström macroglobulinemia: 3 years of follow-up. Blood. 136(18). 2027–2037. 73 indexed citations

7.

Mustafa, Nurulhuda, Wei Jun Jin, Yiling Yu, et al.. (2017). Daratumumab Efficiently Targets NK/T Cell Lymphoma with High CD38 Expression. Blood. 130. 2814–2814. 14 indexed citations

8.

Wu, Lingxiang, Bing Xia, Yuan Tian, et al.. (2017). [Ibrutinib inhibits mesenchymal stem cells-mediated drug resistance in diffuse large B-cell lymphoma].. PubMed. 38(12). 1036–1042. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact